304 related articles for article (PubMed ID: 31581005)
1. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
Elmenier FM; Lasheen DS; Abouzid KAM
Eur J Med Chem; 2019 Dec; 183():111718. PubMed ID: 31581005
[TBL] [Abstract][Full Text] [Related]
2. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
3. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.
Mishra R; Patel H; Alanazi S; Kilroy MK; Garrett JT
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801659
[TBL] [Abstract][Full Text] [Related]
4. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3 kinase in cancer.
Bauer TM; Patel MR; Infante JR
Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
[TBL] [Abstract][Full Text] [Related]
6. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X; Ding J; Meng LH
Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
[TBL] [Abstract][Full Text] [Related]
7. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
Myers AP
Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
[TBL] [Abstract][Full Text] [Related]
8. Drugging PI3K in cancer: refining targets and therapeutic strategies.
Yap TA; Bjerke L; Clarke PA; Workman P
Curr Opin Pharmacol; 2015 Aug; 23():98-107. PubMed ID: 26117819
[TBL] [Abstract][Full Text] [Related]
9. Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review).
Meng D; He W; Zhang Y; Liang Z; Zheng J; Zhang X; Zheng X; Zhan P; Chen H; Li W; Cai L
Pharmacol Res; 2021 Nov; 173():105900. PubMed ID: 34547385
[TBL] [Abstract][Full Text] [Related]
10. Targeting PI3K signaling in cancer: Challenges and advances.
De Santis MC; Gulluni F; Campa CC; Martini M; Hirsch E
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):361-366. PubMed ID: 30946868
[TBL] [Abstract][Full Text] [Related]
11. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
13. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
14. PI3K inhibitors for cancer therapy: what has been achieved so far?
Wu P; Liu T; Hu Y
Curr Med Chem; 2009; 16(8):916-30. PubMed ID: 19275602
[TBL] [Abstract][Full Text] [Related]
15. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.
Jabbour E; Ottmann OG; Deininger M; Hochhaus A
Haematologica; 2014 Jan; 99(1):7-18. PubMed ID: 24425689
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
17. Isoform-Selective PI3K Inhibitors for Various Diseases.
Bheemanaboina RRY
Curr Top Med Chem; 2020; 20(12):1074-1092. PubMed ID: 31903879
[TBL] [Abstract][Full Text] [Related]
18. Development of anti-breast cancer PI3K inhibitors based on 7-azaindole derivatives through scaffold hopping: Design, synthesis and in vitro biological evaluation.
Yang C; Lu M; Chen Y; Xiang R; Qiu T; Jia Y; Yang Y; Liu X; Deng M; Ling Y; Zhou Y
Bioorg Chem; 2021 Dec; 117():105405. PubMed ID: 34649154
[TBL] [Abstract][Full Text] [Related]
19. Advances in the researches on the biological activities and inhibitors of phosphatidylinositol 3-kinase.
Tang JF; Wen Q; Sun J; Zhang WM; Zhu HL
Anticancer Agents Med Chem; 2014 Jun; 14(5):673-87. PubMed ID: 24164048
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020).
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Expert Opin Ther Pat; 2021 Oct; 31(10):877-892. PubMed ID: 33970742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
